Branimycins B and C, Antibiotics Produced by the Abyssal Actinobacterium Pseudonocardia carboxydivorans M‑227

Two new antibiotics, branimycins B (2) and C (3), were produced by fermentation of the abyssal actinobacterium Pseudonocardia carboxydivorans M-227, isolated from deep seawater of the Avilés submarine Canyon. Their structures were elucidated by HRMS and NMR analyses. These compounds exhibit antibac...

Full description

Saved in:
Bibliographic Details
Published inJournal of natural products (Washington, D.C.) Vol. 80; no. 2; pp. 569 - 573
Main Authors Braña, Alfredo F, Sarmiento-Vizcaíno, Aida, Pérez-Victoria, Ignacio, Otero, Luis, Fernández, Jonathan, Palacios, Juan José, Martín, Jesús, de la Cruz, Mercedes, Díaz, Caridad, Vicente, Francisca, Reyes, Fernando, García, Luis A, Blanco, Gloria
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society and American Society of Pharmacognosy 24.02.2017
Amer Chemical Soc
Subjects
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - isolation & purification
Anti-Bacterial Agents - pharmacology
Chemistry, Medicinal
Enterococcus faecalis
Gram-Negative Bacteria
Gram-Positive Bacteria
Haemophilus influenzae
Life Sciences & Biomedicine
Macrolides - chemistry
Macrolides - isolation & purification
Macrolides - pharmacology
Methicillin-Resistant Staphylococcus aureus - drug effects
Microbial Sensitivity Tests
Molecular Structure
Nuclear Magnetic Resonance, Biomolecular
Pharmacology & Pharmacy
Plant Sciences
Science & Technology
SECONDARY METABOLITES
CANTABRIAN SEA
CORAL
STRATEGIES
Online AccessGet full text

Cover

More Information
Summary:Two new antibiotics, branimycins B (2) and C (3), were produced by fermentation of the abyssal actinobacterium Pseudonocardia carboxydivorans M-227, isolated from deep seawater of the Avilés submarine Canyon. Their structures were elucidated by HRMS and NMR analyses. These compounds exhibit antibacterial activities against a panel of Gram-positive bacteria, including Corynebacterium urealyticum, Clostridium perfringens, and Micrococcus luteus, and against the Gram-negative bacterium Neisseria meningitidis. Additionally, branimycin B displayed moderate antibacterial activity against other Gram-negative bacteria such as Bacteroides fragilis, Haemophilus influenzae, and Escherichia coli, and branimycin C against the Gram-positive Enterococcus faecalis and methicillin-sensitive and methicillin-resistant Staphylococcus aureus.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0163-3864
1520-6025
DOI:10.1021/acs.jnatprod.6b01107